ONCT Oncternal Therapeutics Inc
9,680
$9.00
$0.39
(4.53%)
| Watchers | 9,680 |
| 52-Wk Low | $5.57 |
| 52-Wk High | $13.14 |
| Market Cap | $26.64M |
| Volume | 5,861.00 |
| 52-Wk High | $13.14 |
| 52-Wk Low | $5.57 |
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerGlobe Newswire • 2 months ago
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Share to Feed
StockNews.com upgraded shares of Oncternal Therapeutics (NASDAQ:ONCT Free Report) from a sell rating to a hold rating in a research report released on Friday morning.
A number of other...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Joint (JYNT Research Report), Xtant Medical Holdings...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to...
Oncternal Therapeutics (NASDAQ:ONCT) publiera ses derniers b n fices ce jeudi, 7 mars. Pour en savoir plus ce sujet, veuillez consulter ce guide aux b n fices du quatri me trimestre publi s...
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...